CSL share price ‘will be significantly bigger from this point’: fundie

A woman in workout gear flexes her muscles while holding a juiceA woman in workout gear flexes her muscles while holding a juice

The CSL Limited (ASX: CSL) share price has fallen around 20% since the recent high in November 2021. One fund manager thinks that the healthcare business is an opportunity.

CSL is one of the biggest healthcare businesses in Australia, specialising in developing biotherapies and influenza vaccines.

Ben Clark from TMS Capital was talking with Livewire about the market volatility we’ve seen recently.

Clark suggests it’s a good time to be looking at higher-quality names that have been sold off.

Businesses with “pricing power, strong balance sheets and can grow despite what the economy will do” are the ones to focus on. Clark said to Livewire:

A lot of high-quality growth stocks are down at least 50% since 1 January. They’re, arguably, where you want to be in this uncertain environment, in companies that can grow between 10% and 30% regardless of what the economy does.

Focus on the long term

Clark has a portfolio of names, including CSL, that are viewed as high quality. They include ResMed (ASX: RMD), REA Group Limited (ASX: REA), SEEK Limited (ASX: SEK), Macquarie Group Ltd (ASX: MQG), and Wesfarmers Ltd (ASX: WES).

His advice for nervous investors is to invest for the longer term and not worry about what’s happening each week with the ASX share market.

If you’re in high-quality growth businesses, you can take a long-term view. If you’re in speculative stocks you do need to be worried, because there are a lot of businesses that might never come back.

But try not to react on a day-to-day basis, think truly five years ahead and stick to your plan.

Lower share prices hurt… but they could be opportunities

Understandably, some investors are finding this period a bit stressful. But for Clark, owning businesses like CSL makes it a bit easier to get through this period.

In his opinion, the CSL share price (and others) could recover nicely and grow from here.

Clark said, according to Livewire:

I’m not losing any sleep owning those businesses through this cycle – it’s not fun seeing the share prices lower than where they should be, but those companies will be significantly bigger from this point.

CSL expectations

While the company can’t make any commitments regarding the CSL share price, it has provided guidance about its expected FY22 net profit after tax (NPAT). The guidance is for NPAT of between US$2.15 billion to US$2.25 billion at constant currency. That includes $90 million to $110 million in transaction costs related to the agreement to acquire Vifor Pharma.

In mid-February, the ASX healthcare share noted that following initiatives it had implemented in its plasma collections network, collections had been improving and were expected to underpin “stronger sales” in its core plasma therapies. Strong influenza vaccine demand was helping Seqirus (which comes under the CSL group).

The acquisition of Vifor Pharma has been delayed. Vifor Pharma is a global specialty pharmaceutical company with “leadership in renal disease and iron deficiency”.

CSL share price valuation

According to CommSec, the CSL share price is valued at 36x FY22’s estimated earnings.

The post CSL share price ‘will be significantly bigger from this point’: fundie appeared first on The Motley Fool Australia.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.* Scott just revealed what he believes could be the “five best ASX stocks” for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now

See The 5 Stocks
*Returns as of January 12th 2022

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#43B02A”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43B02A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. and ResMed Inc. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed Inc. and Wesfarmers Limited. The Motley Fool Australia has recommended Macquarie Group Limited, REA Group Limited, and SEEK Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/6kxBLAm

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s